References
- Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–1096. doi:https://doi.org/10.1016/S0140-6736(09)60318-4
- Wolk A, Gridley G, Svensson M, Nyrén O, McLaughlin JK, Fraumeni JF, Adam HO. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001;12(1):13–21. doi:https://doi.org/10.1023/a:1008995217664
- Bertrand KA, Giovannucci E, Zhang SM, Laden F, Rosner B, Birmann BM. A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. Cancer Prev Res (Phila). 2013;6(8):864–873. doi:https://doi.org/10.1158/1940-6207.CAPR-13-0132
- Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384(9945):755–765. doi:https://doi.org/10.1016/S0140-6736(14)60892-8
- Abar L, Sobiecki JG, Cariolou M, Nanu N, Vieira AR, Stevens C, Aune D, Greenwood DC, Chan DSM, Norat T, et al. Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies. Ann Oncol. 2019;30(4):528–541. doi:https://doi.org/10.1093/annonc/mdz045
- Shen N, Fu P, Cui B, Bu CY, Bi JW. Associations between body mass index and the risk of mortality from lung cancer: A dose-response PRISMA-compliant meta-analysis of prospective cohort studies. Medicine (Baltimore). 2017;96(34):e7721. doi:https://doi.org/10.1097/MD.0000000000007721
- Waalkes S, Merseburger AS, Kramer MW, Herrmann TRW, Wegener G, Rustemeier J, Hofmann R, Schrader M, Kuczyk MA, Schrader AJ, et al. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control. 2010;21(11):1905–1110. doi:https://doi.org/10.1007/s10552-010-9618-2
- Ewertz M, Jensen M-B, Gunnarsdóttir KÁ, Højris I, Jakobsen EH, Nielsen D, Stenbygaard LE, Tange UB, Cold S. Effect of obesity on prognosis after early-stage breast cancer. JCO. 2011;29(1):25–31. doi:https://doi.org/10.1200/JCO.2010.29.7614
- Ugai T, Ito H, Oze I, Saito E, Rahman MS, Boffetta P, Gupta PC, Sawada N, Tamakoshi A, Shu XO, et al. Association of BMI, smoking, and alcohol with multiple myeloma mortality in Asians: a pooled analysis of more than 800,000 participants in the Asia Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2019;28(11):1861–1867. doi:https://doi.org/10.1158/1055-9965.EPI-19-0389
- Li T, Liu ZG, Liang PQ, Wang HT. Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China. Leuk Lymphoma. 2017;58(7):1624–1629. doi:https://doi.org/10.1080/10428194.2016.1257793
- Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, Fu Q, Chang S-H, Colditz GA. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. JCO. 2012;30(26):3217–3222. doi:https://doi.org/10.1200/JCO.2011.39.2100
- Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R, Egle A. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol. 2014;25(1):171–176. doi:https://doi.org/10.1093/annonc/mdt481
- Kanemasa Y, Shimoyama T, Sasaki Y, Tamura M, Sawada T, Omuro Y, Hishima T, Maeda Y. Analysis of the prognostic value of BMI and the difference in its impact according to age and sex in DLBCL patients. Hematol Oncol. 2018;36(1):76–83. doi:https://doi.org/10.1002/hon.2426
- Geyer SM, Morton LM, Habermann TM, Allmer C, Davis S, Cozen W, Severson RK, Lynch CF, Wang SS, Maurer MJ, et al. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin llymphoma. Cancer. 2010;116(12):2993–3000. doi:https://doi.org/10.1002/cncr.25114
- Hohloch K, Altmann B, Pfreundschuh M, Loeffler M, Schmitz N, Zettl F, Ziepert M, Trümper L. Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group. Br J Haematol. 2018;180(2):236–245. doi:https://doi.org/10.1111/bjh.15029
- Coutinho R, Lobato J, Esteves S, Cabecadas J, Gomes da Silva M. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients. Ann Hematol. 2019;98(8):1937–1946. doi:https://doi.org/10.1007/s00277-019-03676-0
- Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, et al. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol. 2014;25(3):669–674. doi:https://doi.org/10.1093/annonc/mdt594
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341. doi:https://doi.org/10.1016/j.ijsu.2010.02.007
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi:https://doi.org/10.1007/s10654-010-9491-z
- Bendtsen MD, Munksgaard PS, Severinsen MT, Bekric E, Brieghel C, Nielsen KB, Brown PdN, Dybkaer K, Johnsen HE, Bøgsted M, et al. Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients. Eur J Haematol. 2017;98(4):355–362. doi:https://doi.org/10.1111/ejh.12835
- Boyle T, Connors JM, Gascoyne RD, Berry BR, Sehn LH, Bashash M, Spinelli JJ. Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases. Br J Haematol. 2017;178(3):442–447. doi:https://doi.org/10.1111/bjh.14702
- Chan H, Jackson S, McLay J, Knox A, Lee J, Wang S, Issa S. Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients. Leuk Lymphoma. 2016;57(11):2584–2592. doi:https://doi.org/10.3109/10428194.2016.1151508
- Mörth C, Valachis A, Abu Sabaa A, Marshall K, Hedström G, Flogegård M, Baecklund E, Enblad G. Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome. Acta Oncol. 2019;58(8):1170–1177. doi:https://doi.org/10.1080/0284186X.2019.1619936
- Park S, Han B, Cho JW, Woo S-y, Kim S, Kim SJ, Kim WS. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer. 2014;66(2):225–233. doi:https://doi.org/10.1080/01635581.2014.867065
- Sarkozy C, Mounier N, Delmer A, Van Hoof A, Karsenti JM, Fleck E, Maerevoet M, Eisenmann JC, Delarue R, Fabbro M, et al. Impact of BMI and gender on outcomes in DLBCL patients treated with R-CHOP: a pooled study from the LYSA. Lymphoma. 2014;2014:1–12. doi:https://doi.org/10.1155/2014/205215
- Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, et al. High body mass index in elderly patients with DLBCL treated with rituximab-containing therapy compensates for negative impact of male sex. J Natl Compr Canc Netw. 2016;14(10):1274–1281. doi:https://doi.org/10.6004/jnccn.2016.0136
- Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1988;6(8):1321–1327. doi:https://doi.org/10.1200/JCO.1988.6.8.1321
- Sparreboom A, Wolff AC, Mathijssen RHJ, Chatelut E, Rowinsky EK, Verweij J, Baker SD. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. JCO. 2007;25(30):4707–4713. doi:https://doi.org/10.1200/JCO.2007.11.2938
- Müller C, Murawski N, Wiesen MHJ, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119(14):3276–3284. doi:https://doi.org/10.1182/blood-2011-09-380949
- Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol. 1995;36(6):473–476. doi:https://doi.org/10.1007/BF00685796
- Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F. Therapy insight: cancer anorexia-cachexia syndrome-when all you can eat is yourself. Nat Clin Pract Oncol. 2005;2(3):158–165. doi:https://doi.org/10.1038/ncponc0112
- Stevenson JKR, Qiao Y, Chan KKW, Beca J, Isaranuwatchai W, Guo H, Schwartz D, Arias J, Gavura S, Dai WF, et al. Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent. Leuk Lymphoma. 2019;60(6):1399–1408. doi:https://doi.org/10.1080/10428194.2018.1538509
- Wang J, Xu H, Zhou S, Wang D, Zhu L, Hou J, Tang J, Zhao J, Zhong S. Body mass index and mortality in lung cancer patients: a systematic review and meta-analysis. Eur J Clin Nutr. 2018;72(1):4–17. doi:https://doi.org/10.1038/ejcn.2017.70
- Zhao B, Zhang J, Zhang J, Zou S, Luo R, et al. The impact of preoperative underweight status on postoperative complication and survival outcome of gastric cancer patients: a systematic review and meta-analysis. Nutr Cancer. 2018;70:1254–1263.
- Chang WC, Yang CY, Lin CS, Lin CK, Chen YW. Pretreatment body mass index as a prognostic predictor in patients with oral squamous cell carcinoma. Clin Oral Invest. 2020;24(8):2781–2788. doi:https://doi.org/10.1007/s00784-019-03141-2
- Petermann-Rocha F, Chen M, Gray SR, Ho FK, Pell JP, Celis-Morales C. Factors associated with sarcopenia: a cross-sectional analysis using UK Biobank. Maturitas. 2020;133:60–67. doi:https://doi.org/10.1016/j.maturitas.2020.01.004
- Go S-I, Park S, Kang MH, Kim H-G, Kim HR, Lee G-W. Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma. Ann Hematol. 2019;98(2):401–411. doi:https://doi.org/10.1007/s00277-018-3540-1
- Zhou Q, Wei Y, Huang F, Wei X, Wei Q, Hao X, Zhang Y, Feng R. Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP. Int J Hematol. 2016;104(4):485–490. doi:https://doi.org/10.1007/s12185-016-2052-9
- Camus V, Lanic H, Kraut J, Modzelewski R, Clatot F, Picquenot JM, Contentin N, Lenain P, Groza L, Lemasle E, et al. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol. 2014;93(1):9–18. doi:https://doi.org/10.1111/ejh.12285